Reliable delivery *at* constant rates.

ALZET® Osmotic Pumps—providing accurate drug delivery for over 20 years.

By ensuring the dependable delivery of biological, chemical or therapeutic agents, either systemically or to a targeted tissue or organ, ALZET osmotic pumps can help ensure the reliability of your data. Using one of ten osmotic pump models which feature a variety of rates and durations, you can continuously deliver diverse compounds to unrestrained animals. You can even use a brain infusion kit for direct delivery to the central nervous system.

CONTINUOUS DELIVERY CAN SAVE RESEARCHER TIME.

For more than 20 years, ALZET osmotic pumps have helped researchers save critical research time by eliminating the need for frequent, round-the-clock injections. And with zero order delivery, these pumps have proven invaluable in ensuring that predictable compound levels are sustained at therapeutic concentrations, avoiding potentially toxic or misleading side effects.



In fact, more than 5,200 published references attest to the remarkable reliability of these unique self-powered pumps. To learn how you can employ these well proven delivery systems, visit www.alza.com/alzet/rates or call 1-800-692-2990 or 650-962-2251.

alzet®
OSMOTIC PUMPS
www.alza.com/alzet/rates
alzet@alza.com

See us at ASHG Booth #434

Discover DNA Sequence Variations *Without* Sequencing or Gels

TRANSGENOMIC

wave™

DNA Fragment Analysis System with DNASep® Technology

- *Mutation Detection*
- *Polymorphism Screening*
- *Genotyping*
- *Size-Based DNA Fragment Separations*









The WAVE™ DNA Fragment Analysis System is a fully integrated instrument that performs rapid, automated separation and quantification of single- and double-stranded DNA fragments.

Screen for Unknown Mutations and Polymorphisms

Unlike mass sequencing techniques, the WAVE system determines DNA variants quickly and easily. Single nucleotide and short tandem repeat polymorphisms (SNPs, STRs) are detected by resolving the heteroduplexes and homoduplexes formed using the WAVE system's precisely controlled partially denaturing conditions.

Full Automation from Sampling through Analysis

The built-in autosampler accommodates 96-well PCR* plates for high-throughput screening. Computer control of all run parameters permits unattended operation and ensures excellent run-to-run reproducibility. Data can be viewed in real-time and processed immediately or archived for analysis at your convenience.

Results in Minutes

With results in just 5 to 7 minutes, you'll cut project completion time dramatically. Automated fragment collection (optional) makes samples immediately available for subsequent PCR or analysis.

Ask About Our FREE Sample Analysis Program

Don't waste any more time running gels. Send us your most challenging samples, and we'll show you superior results that only the WAVE system can provide.

For additional information:

In North America, call: **1.800.369.2822**
In Europe, call: **+44.1270.258669**
Elsewhere, call the U.S.: **1.408.432.3230**

Email: **info@transgenomic.com**
Or visit: **www.transgenomic.com**

TRANSGENOMIC™
transforming the world

*PCR is a process covered by patents owned by Hoffmann-LaRoche.

CALL FOR PROPOSALS

ASCO-JANSSEN *RAS*-RELATED TRANSLATIONAL RESEARCH GRANT PROGRAM



Janssen is pleased to announce that it has agreed to support an ASCO Young Investigator Award with the intent to support research in the general area of signal transduction. ASCO's guidelines stress the importance of a goal to make the results ultimately clinically relevant.

The ability to understand signal transduction pathways will hopefully enable physicians to intervene at the fundamental cellular level in the disease process. This should result in drugs with greater efficacy and fewer adverse effects than conventional cytotoxic or hormonal anticancer therapy.

ASCO invites applications for a grant of $35,000 (total costs) of one year's duration. ASCO anticipates that a successful applicant may apply for a second year of support during the first year support. If the program is successful, it is anticipated that in subsequent years, additional applications will be sought.

This program is part of Janssen's commitment to the research and development of new anticancer agents.

Eligibility

Applications are encouraged from fellows and medical professionals in the field of oncology. Multiple submissions will be considered. However, each applicant may receive only one grant.

Applicants must be fellows of an academic institution with an identified sponsor (who is an ASCO member) and mentor. Applicants who are not active members of ASCO must apply for membership with the Society.

Time Table

The application schedule is:

Deadline for receipt of applications .....November 13, 1998
Grant awarded .....May 1999 ASCO Annual Meeting

Applications will be reviewed by the ASCO Grants Selection Committee in February 1999. Notifications of acceptance are sent to applicants in mid-March 1999.

To receive the official Young Investigator Award application by mail, please contact:

American Society of Clinical Oncology
Department of Science and Education
225 Reinekers Lane, Suite 650
Alexandria, VA 22314

Phone: 703-299-1070 • Fax: 703-299-1044 • E-mail: ulepicl@asco.org

Applications must be received at the ASCO headquarters on or before Friday, November 13, 1998.

JANSSEN · PHARMACEUTICA · RESEARCH FOUNDATION ·

CALL FOR APPLICATIONS

Center for Inherited Disease Research

The Center for Inherited Disease Research (CIDR) is a resource to provide high throughput genotyping services to research efforts that are attempting to identify genetic loci and allelic variants involved in human disease. CIDR concentrates primarily on multifactorial hereditary disease in humans although linkage analysis of single gene disorders can also be accommodated. Using samples provided by the principal investigators, CIDR carries out genome-wide scans for parametric and non-parametric linkage analysis using automated fluorescent technology to detect microsatellite markers with ~10 cM average spacing. Consultation on study design and statistical analysis are available as additional, and optional, services to investigators. The data and analyses will remain the property of the principal investigator and, once the studies in CIDR are complete, will be returned to the principal investigators for further research.

CIDR is a joint effort by eight participating institutes at NIH: the National Cancer Institute (NCI), the National Human Genome Research Institute (NHGRI), the National Institute of Child Health and Human Development (NICHD), the National Institute on Deafness and Other Communication Disorders (NIDCD), the National Institute on Drug Abuse (NIDA), the National Institute of Environmental Health Sciences (NIEHS), the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS). CIDR is located at the Bayview Research Campus of the Johns Hopkins University and is operated by the university through a contract from the NIH.

For a special introductory period, investigators whose projects are supported by one of the eight NIH Institutes participating in CIDR will receive free genotyping. Other investigators supported by an NIH Institute not participating in CIDR or from another governmental or non-profit institution will be charged $1.00 per genotype (DNA sample x microsatellite marker).

Access to CIDR is open to all investigators on a competitive basis through peer review. For a more complete description of CIDR, including specific application procedures, visit our Website at http://www.cidr.jhmi.edu/. If you would like additional information, contact Dr. Jerry Roberts, Scientific Review Administrator and Executive Director, CIDR Board of Governors, in the NHGRI Office of Scientific Review.

Application Deadlines

March 1
July 1
November 1

Jerry Roberts, Ph.D.
National Institutes of Health
National Human Genome Research Institute
38 Library Drive MSC 6050
Building 38A, Room 609
Bethesda, MD 20892-6050
(301) 402-0838
FAX (301) 480-2770
jerry_roberts@nhgri.nih.gov

FDA-NCI Food and Drug Administration · National Cancer Institute

Workshop on Tumor Vaccines

Masur Auditorium, National Institutes of Health

December 10, 1998 - 7:30 a.m. to 5:00 p.m.
December 11, 1998 - 8:00 a.m. to 5:30 p.m.



The purpose of the meeting is to discuss the current state of tumor vaccine development and characterization and potency tests for various classes of cell vaccines. Other major discussions will include the detection of tumor cell contamination in immunotherapy products and immunological assessments in early clinical trials.

Session I: Regulatory Considerations in Tumor Vaccines

Session II: Phenotypic and Functional Characterization of Dendritic Cells (DC) or Other Antigen Presenting Cells (APC)

Session III: Autologous and Allogeneic Tumor Cells as Tumor Vaccines

Session IV: Preclinical Strategies and Immunological Assessments in Early Clinical Trials of Tumor Vaccines

Session V: Detection and Characterization of Tumor Cells in Cellular Vaccines

For additional details, contact:
Karen Blackburn
TASCON, Inc.
1803 Research Blvd., Suite 305
Rockville, MD 20850
Phone: (301) 315-9000, ext. 514
Fax: (301) 738-9786
E-mail: kblackburn@tascon.com

FACULTY POSITION
COLON CANCER RESEARCH
INSTRUCTOR LEVEL

A faculty position in colon cancer research at the instructor level is available at the Ireland Cancer Center at Case Western Reserve University and University Hospitals of Cleveland. The successful candidate should have five years of postdoctoral level experience in signal transduction and molecular biology as well as familiarity with colon cancer, TGF-beta signaling, and microarray technology. As an Instructor at Case Western Reserve University, this individual will be responsible for providing supervision to graduate students in the laboratory.

SEND LETTER OF APPLICATION TO

Sanford Markowitz, M.D., Ph.D.
UCRC 2, Suite 200
11001 Cedar Avenue
Cleveland, Ohio 44106

CASE WESTERN RESERVE UNIVERSITY | **IRELAND CANCER CENTER**

CWRU is an AA/EEO/ADA employer and encourages applications from women and minorities.

A New Resource Kit from the National Cancer Institute

- *Cancer Research challenges, advances, and opportunities*
- *Cancer Statistics*
- *Research Initiatives*
- *Clinical Studies... and more*

To order, call NCI's Cancer Information Service at

1-800-4-CANCER
(1-800-422-6237)

People with TTY equipment, dial 1-800-332-8615

Research Scientist

Cedars-Sinai Medical Center's Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, is recruiting for a PHD, MD or MD/PHD Scientist. The Department consists of faculty with research interests in cellular and molecular biology. Preference will be given to individuals with an exciting research program focused on ovarian and/or breast cancer. An interest in tumorigenesis, molecular genetics, growth factors and translational studies is highly desired. We offer a busy clinical service and tumor bank which provides ample human tumor specimens for study.

Cedars-Sinai is affiliated with the University of California at Los Angeles' School of Medicine and all academic faculty appointments must meet the criteria of the University for Assistant or Associate level. The deadline for applications is October 31, 1998.

Applications should include a curriculum vitae, statement of research interests, status of current funding, and salary requirements to: **Rebecca Chandler, Human Resources Manger/Academic Services, 8723 Alden Drive, SSB-110, Los Angeles, CA 90048, FAX: (310) 659-9276.** EOE/AA Women and minority applicants are strongly encouraged.

CEDARS-SINAI MEDICAL CENTER

JOURNAL OF NEUROVIROLOGY

CALL FOR PAPERS IN CNS TUMOR BIOLOGY

***JNV** is exclusively dedicated to the characterisation, molecular biology, pathogenesis and sequalae of diseases of the nervous system that are directly and/or indirectly induced by viruses. In view of recent developments in the understanding of molecular pathogenesis and genetics and genetics of cancer through the use of viral proteins as probes, and the employment of neurotropic viral vectors for gene delivery to the brain, the Journal of NeuroVirology has increased its scope to include publications in the areas of brian tumor biology, neuroncology, and brain tumor treatment. As such, **JNV** will continue to provide a unique forum for the communication between basic and physician scientists with a common goal towards (i) understanding the molecular pathogenesis of viral and non-viral induced neurological diseases, and (ii) the development of effective and safe molecular therapeutic strategies against diseases of the nervous system.*

JNV is welcoming authors to submit basic research articles and clinical reports from the following areas:

- Neuro-AIDS
- Neurodegenerative disorders
- Brain tumor biology/neuro-oncology
- Transmissable encephalopathies
- Neuro-immune interactions and neuro-inflammatory diseases
- Gene therapy

JNV's International Editorial Board consists of the leading basis scientists and clinicians in the areas of neurovirology, NeuroAIDS, neuro-immunology, and neurodegenerative disorders. The current distinguished Editorial Board will benefit from its well accomplished and internationally known experts in the areas of neuro-oncology and transmissable encephalopathies, and will ensure publications **of the highest** caliber in the Journal of NeuroVirology.

JNV will continue to devote special issues to specific topics in order to review progress in the field both at the bench and in the clinic, to bring the latest discoveries to its readership. Our most recent special issue (April 1998) is devoted to brain tumors. Upcoming special issues will include NeuroAIDS (June 1998) which will also cover the Neuroscience of HIV Infections Conference, and **the Role of** Chemonkines in Neurodegenerative Diseases **(December** 1998).

Contributors are invited to send manuscripts to the:

Editor-in-Chief, Kamel Khalili, Ph.D.
Editorial Office
Journal of NeuroVirology
Centre for NeuroVirology and NeuroOncology
Allegheny University of the Health Sciences
245 North 15th Street
Mailstop 406
Philadelphia
PA 19102 USA

Tel: 1 215 762 7870
Fax: 1 215 762 8328
Email: jnv@auhs.edu

JNV has world-wide coverage in major databases:

- Current Contents
- MEDLINE
- SciSearch
- Cambridge Scientific Abstracts
- Research Alert
- SUBIS
- Neuroscience Citation Index

Can you afford NOT to have your paper published in JNV

STOCKTON

To receive the Instructions to Authors or a FREE sample copy of JNV, please complete the form, and return to:

Sharon Marshall
Stockton Press, Houndmills
Basingstoke, Hants RG21 6XS, UK
Tel: +44 (0) 1256 351898
Fax: +44 (0) 1256 328339
e-mail: s.marshall@stockton-press.co.uk

North America:
Toll Free: 1 800 747 3187

Name:.....

Address:.....

.....

Tel: .....

Fax: .....

Email:.....

JNV 98/CR